These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 32028327)

  • 1. Aging does not impact drug--drug interaction magnitudes with antiretrovirals.
    Stader F; Decosterd L; Stoeckle M; Cavassini M; Battegay M; Saldanha SA; Marzolini C; Courlet P;
    AIDS; 2020 May; 34(6):949-952. PubMed ID: 32028327
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic profiles of boosted darunavir, dolutegravir and lamivudine in aging people living with HIV.
    Courlet P; Stader F; Guidi M; Alves Saldanha S; Stoeckle M; Cavassini M; Battegay M; Buclin T; Decosterd LA; Marzolini C;
    AIDS; 2020 Jan; 34(1):103-108. PubMed ID: 31490233
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Unveiling the basis of antiretroviral therapy-induced osteopenia: the effects of Dolutegravir, Darunavir and Atazanavir on osteogenesis.
    Cazzaniga A; Scrimieri R; Galli M; Maier J; Rusconi S
    AIDS; 2021 Feb; 35(2):213-218. PubMed ID: 33394669
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Short-cycle therapy (5 days on/2 days off) with a lamivudine + dolutegravir regimen in a cohort of virologically suppressed patients with HIV infection.
    Lanzafame M; Lattuada E; Gottardo R; Piacentini D; Be G; Razzaboni E; Cattaneo P; Luise D; Vento S
    Int J Antimicrob Agents; 2021 Mar; 57(3):106290. PubMed ID: 33513407
    [No Abstract]   [Full Text] [Related]  

  • 5. Drug-Drug Interactions Between Antiretrovirals and Carbamazepine/Oxcarbazepine: A Real-Life Investigation.
    Cattaneo D; Baldelli S; Cozzi V; Fusi M; Atzori C; Micheli V; Filice C; Gervasoni C
    Ther Drug Monit; 2020 Apr; 42(2):330-334. PubMed ID: 31743292
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brief Report: Integrase Strand Transfer Inhibitors Are Associated With Lower Risk of Incident Cardiovascular Disease in People Living With HIV.
    O'Halloran JA; Sahrmann J; Butler AM; Olsen MA; Powderly WG
    J Acquir Immune Defic Syndr; 2020 Aug; 84(4):396-399. PubMed ID: 32243280
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-Term Safety and Efficacy of Dolutegravir in Treatment-Experienced Adolescents With Human Immunodeficiency Virus Infection: Results of the IMPAACT P1093 Study.
    Viani RM; Ruel T; Alvero C; Fenton T; Acosta EP; Hazra R; Townley E; Palumbo P; Buchanan AM; Vavro C; Singh R; Graham B; Anthony P; George K; Wiznia A;
    J Pediatric Infect Dis Soc; 2020 Apr; 9(2):159-165. PubMed ID: 30951600
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Carbamazepine on Darunavir Trough Concentrations: When the Dose Can Make the Difference-A Case Study.
    Cattaneo D; Caloni B; Caronni S; Calvagna N; Bonini I; Giacomelli A; Gervasoni C
    Ther Drug Monit; 2024 Jun; 46(3):277-280. PubMed ID: 38723113
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Physiologically-Based Pharmacokinetic Modeling Combined with Swiss HIV Cohort Study Data Supports No Dose Adjustment of Bictegravir in Elderly Individuals Living With HIV.
    Stader F; Courlet P; Decosterd LA; Battegay M; Marzolini C
    Clin Pharmacol Ther; 2021 Apr; 109(4):1025-1029. PubMed ID: 33521960
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimizing concentrations of concomitant antiretrovirals by reducing etravirine doses: two case reports of complex drug-drug interactions.
    Denault JS; Cabot JF; Langlois H; Marcotte S; Sheehan NL
    Antivir Ther; 2019; 24(1):73-76. PubMed ID: 30353885
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Doing More With Less: Review of Dolutegravir-Lamivudine, a Novel Single-Tablet Regimen for Antiretroviral-Naïve Adults With HIV-1 Infection.
    Santevecchi BA; Miller S; Childs-Kean LM
    Ann Pharmacother; 2020 Dec; 54(12):1252-1259. PubMed ID: 32517480
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of dolutegravir plus emtricitabine versus standard ART for the maintenance of HIV-1 suppression: 48-week results of the factorial, randomized, non-inferiority SIMPL'HIV trial.
    Sculier D; Wandeler G; Yerly S; Marinosci A; Stoeckle M; Bernasconi E; Braun DL; Vernazza P; Cavassini M; Buzzi M; Metzner KJ; Decosterd LA; Günthard HF; Schmid P; Limacher A; Egger M; Calmy A;
    PLoS Med; 2020 Nov; 17(11):e1003421. PubMed ID: 33170863
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 2019 update of the European AIDS Clinical Society Guidelines for treatment of people living with HIV version 10.0.
    Ryom L; Cotter A; De Miguel R; Béguelin C; Podlekareva D; Arribas JR; Marzolini C; Mallon P; Rauch A; Kirk O; Molina JM; Guaraldi G; Winston A; Bhagani S; Cinque P; Kowalska JD; Collins S; Battegay M;
    HIV Med; 2020 Nov; 21(10):617-624. PubMed ID: 32885559
    [TBL] [Abstract][Full Text] [Related]  

  • 14. UHPLC-MS/MS assay for simultaneous determination of amlodipine, metoprolol, pravastatin, rosuvastatin, atorvastatin with its active metabolites in human plasma, for population-scale drug-drug interactions studies in people living with HIV.
    Courlet P; Spaggiari D; Desfontaine V; Cavassini M; Alves Saldanha S; Buclin T; Marzolini C; Csajka C; Decosterd LA
    J Chromatogr B Analyt Technol Biomed Life Sci; 2019 Sep; 1125():121733. PubMed ID: 31374423
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of comedications and potential drug-drug interactions in people living with HIV in China.
    Chen R; Chen J; Tang Q; Meng Z; Luo L; Zhang W; Deng A; Zhang L; Wang J; Qi T; Zhang R; Shen Y; Liu L; Steinhart C; Lu H
    J Infect Chemother; 2020 Jul; 26(7):722-728. PubMed ID: 32354599
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of scaling up dolutegravir on antiretroviral resistance in South Africa: A modeling study.
    Hauser A; Kusejko K; Johnson LF; Günthard HF; Riou J; Wandeler G; Egger M; Kouyos RD
    PLoS Med; 2020 Dec; 17(12):e1003397. PubMed ID: 33315863
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dolutegravir with boosted darunavir as treatment simplification for treatment-experienced HIV patients with multiple mutations.
    Paparizos V; Vasalou V; Kourkounti S
    Int J STD AIDS; 2019 Oct; 30(12):1214-1215. PubMed ID: 31775586
    [No Abstract]   [Full Text] [Related]  

  • 18. Perspectives on the Barrier to Resistance for Dolutegravir + Lamivudine, a Two-Drug Antiretroviral Therapy for HIV-1 Infection.
    Boffito M; Waters L; Cahn P; Paredes R; Koteff J; Van Wyk J; Vincent T; Demarest J; Adkison K; Quercia R
    AIDS Res Hum Retroviruses; 2020 Jan; 36(1):13-18. PubMed ID: 31507204
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Longitudinal trends and determinants of patient-reported side effects on ART-a Swedish national registry study.
    Mellgren Å; Eriksson LE; Reinius M; Marrone G; Svedhem V
    PLoS One; 2020; 15(12):e0242710. PubMed ID: 33362248
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV-1 diversity and the implementation of integrase strand-transfer inhibitors as part of combination antiretroviral therapy.
    Mikasi SG; Ikomey GM; Obasa AE; Cloete R; Jacobs GB
    S Afr Med J; 2020 Aug; 110(9):13071. PubMed ID: 32880259
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.